Doug Muchmore, MD
Diasome, Cleveland, Ohio
Dr. Muchmore is a board certified endocrinologist who practiced tertiary care specialty medicine at Scripps Clinic and Research Foundation for 13 years prior to joining Eli Lilly and Co. where he served as Physician Group Leader for the development of raloxifene hydrochloride for the prevention and treatment of osteoporosis. He then led the Phase 1,2 and 3 clinical development of Lilly’s inhaled insulin program for eight years, after which he joined Halozyme Therapeutics as Vice President for Endocrinology Clinical Development in charge of the development of Halozyme’s ultrafast insulin program for seven years. In addition to leadership in clinical product development, Dr. Muchmore has had abundant experience with FDA interactions, successfully influencing FDA perspectives on product development in several instances. Since the middle of 2015 Dr. Muchmore has been clinical development and regulatory strategy expert consultant with Kinexum, a strategic advisory firm founded by Dr. Alexander Fleming. Dr. Muchmore has been a consultant to Diasome since the beginning of 2017, and is now serving as Chief Technology Officer.
While at Lilly Dr. Muchmore received numerous corporate leadership and brand advocacy awards, including election to the Eli Lilly President’s Council. He has author numerous papers in the fields of insulin mechanism of action, osteoporosis treatment and insulin product development.
Dr. Muchmore is a graduate of Stanford University and University of California, San Diego School of Medicine. He served as intern and resident in internal medicine at the University of Washington, Seattle and then as fellow and clinical instructor in endocrinology and metabolism at University of Washington Hospital, Seattle.